支持新型抗生素治疗多重耐药菌感染疗效的数据评估
11种新药基于20项非劣效试验获批,多数试验中耐药菌比例低且排除免疫抑制和危重患者;上市后针对耐药菌的随机对照试验仅2项共116例,疗效数据稀缺。
要点
- 11种抗多重耐药菌新药基于20项非劣效试验获批,适应症多为常见感染。
- 多数试验中耐药菌比例低(革兰阴性<10%,革兰阳性肺炎<1%)。
- 上市后仅2项随机对照试验专门针对耐药菌感染,共116例。
核心结论
- 抗多重耐药菌新药的获批基于非耐药菌感染的非劣效试验,且排除最可能需要这些药物的患者,上市后疗效数据稀缺。
主要发现
- 11种新获批抗多重耐药菌抗生素的初始批准由20项试验支持,均为非劣效设计。
- 所有初始批准适应症均为常见感染,主要为急性细菌性皮肤和皮肤结构感染, regardless of causative microorganism。
- 多数试验中多重耐药菌比例低:革兰阴性感染<10%,革兰阳性肺炎<1%。
- 大多数试验(90%)排除了免疫抑制和危重患者。
- 通过ClinicalTrials.gov识别的16项额外上市后随机对照试验中,仅2项专门纳入多重耐药菌感染,共116例患者。
临床怎么用
- 医疗专业人员和监管机构应要求更稳健的数据以支持临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Infections caused by multidrug-resistant (MDR) bacteria are a major public health threat. We aimed to assess the data supporting US Food and Drug Administration (FDA) approval of new agents aimed to treat MDR bacterial infections and the data provided by postmarketing studies. METHODS: We identified all drugs with in vitro activity against MDR bacteria initially approved by the FDA between January 2010 and December 2018. Characteristics of trials supporting approval and regulatory pathways were collected from Drugs@FDA. Characteristics of postmarketing studies were extracted from drug labels and ClinicalTrials.gov entries effective 1 June 2019. RESULTS: Initial approval of 11 newly approved antibiotics with anti-MDR activity was supported by 20 trials, all with noninferiority design. All initially approved indications were for common infections, mostly acute bacterial skin and skin-structure infections, regardless of causative microorganism. The proportion of MDR bacteria in most trials was low (<10% for gram-negative infections, <1% for gram-positive pneumonia). Most trials (90%) excluded immunocompromised and critically ill patients. Of 16 additional postmarketing randomized controlled trials identified through ClinicalTrials.gov, only 2 exclusively included infections caused by MDR bacteria, comprising 116 patients. No drug was granted accelerated approval, which would mandate postmarketing efficacy studies. CONCLUSIONS: The approval of new drugs with potential clinical activity against MDR bacteria is supported by trials evaluating infections caused by non-MDR organisms, using noninferiority design and excluding the patients most likely to require these agents. Subsequent postmarketing efficacy data against these organisms are scarce. Healthcare professionals and regulators should demand more robust data to support clinical decision making.
引用
- Yahav D, Tau N, Shepshelovich D, et al. Assessment of Data Supporting the Efficacy of New Antibiotics for Treating Infections Caused by Multidrug-resistant Bacteria. Clin Infect Dis. 2021. PMID: 32337578. doi:10.1093/cid/ciaa457
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。